Compare SKYT & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYT | ESPR |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 939.6M | 898.5M |
| IPO Year | 2021 | 2013 |
| Metric | SKYT | ESPR |
|---|---|---|
| Price | $16.36 | $3.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $19.40 | $6.86 |
| AVG Volume (30 Days) | 1.6M | ★ 6.4M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.62 | N/A |
| Revenue | ★ $346,587,000.00 | $303,802,000.00 |
| Revenue This Year | $28.48 | $25.45 |
| Revenue Next Year | $41.29 | N/A |
| P/E Ratio | $6.24 | ★ N/A |
| Revenue Growth | 0.19 | ★ 2.83 |
| 52 Week Low | $5.67 | $0.69 |
| 52 Week High | $24.23 | $4.13 |
| Indicator | SKYT | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 54.41 |
| Support Level | $17.78 | $3.72 |
| Resistance Level | $20.88 | $4.13 |
| Average True Range (ATR) | 1.39 | 0.22 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 31.31 | 12.96 |
SkyWater Technology Inc is a U.S.-based, independent, pure-play technology foundry that offers semiconductor development and manufacturing services from its fabrication facilities. In its technology as a service model, it leverages a foundation of proprietary technology, engineering to co-develop process technology intellectual property (IP) with its customers that enable disruptive concepts through its Technology Services for diverse microelectronics (integrated circuits) and related micro- and nanotechnology applications. It focuses on serving diversified, high-growth, end users in numerous vertical markets, including computation, aerospace and defense (A&D), automotive and transportation, bio-health, and industrial.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.